



Special Track Session 4

Oncology and Theranostics Committee

Sunday, October 18, 16:45–18:15

Session Title

Debate: Is There a Role for Radium-223 in the Era of PSMA RLT?

Moderators

Silke Gillessen (Bellinzona, Switzerland)

Matteo Bauckneht (Genova, Italy)

Point of view: Yes, There is Still a Role for Radium-223

Daniela Oprea-Lager (Nijmegen, Netherlands)

Point of view: No, There is No Role for Radium-223 at Present

Stefano Fanti (Bologna, Italy)

The Medical Oncologist's Perspective

Fabio Turco (Bellinzona, Switzerland)

Take-Home Messages: What We Have Learned Today

Matteo Bauckneht (Genova, Italy)

Educational Objectives

1. Understand the evolving role of Radium-223 in the era of PSMA-targeted radioligand therapy (PSMA RLT) for metastatic castration-resistant prostate cancer (mCRPC).
2. Identify the characteristics and clinical management challenges of “dual-eligible” patients suitable for both Radium-223 and PSMA RLT.
3. Critically evaluate current evidence and strategies for treatment sequencing, patient selection, and potential combination approaches involving radiopharmaceuticals and systemic therapies.

Summary

This debate session addresses the controversial role of Radium-223 in the contemporary landscape of PSMA-targeted radioligand therapy for mCRPC. Through opposing expert viewpoints, the session explores whether Radium-223 still has a meaningful clinical role, with a focus on “dual-eligible” patients and key questions around therapeutic sequencing, patient selection, and potential combination strategies. Additional perspectives from medical oncology provide insight into real-world decision-making, and the session concludes with a synthesis of current evidence and future directions in prostate cancer theranostics.

Key Words

Radium-223; PSMA; Radioligand Therapy; mCRPC; Theranostics; Prostate Cancer